Clinical trials · Pennsylvania
Rhabdomyosarcoma clinical trials in Pennsylvania
We’re tracking 7 recruiting rhabdomyosarcoma studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT05304585RecruitingPhase 3
Chemo for children with early, low-risk fusion-negative rhabdomyosarcoma
This Phase 3 study tests a chemotherapy plan for children and teens with newly diagnosed, very low-risk or low-risk rhabdomyosarcoma that does not have certain gene fusions (FOXO1 fusion negative). The goal is to see if this treatment can work well while limiting side effects by matching therapy to early-stage risk.
Allentown, PennsylvaniaAges Up to 21 years - NCT07466316RecruitingPhase 3
Comparing chemo schedules for intermediate-risk rhabdomyosarcoma
This trial compares two different chemotherapy schedules for children and young adults with intermediate-risk rhabdomyosarcoma (a type of muscle cancer). One group gets a higher dose of chemotherapy over a shorter period, while the other gets a lower dose plus maintenance therapy for a longer time. The goal is to see which approach works better.
Allentown, PennsylvaniaAges Up to 50 years - NCT06721689RecruitingPhase 1/Phase 2
PEEL-224 with chemo for pediatric solid tumors
This trial tests a new drug called PEEL-224 combined with two chemotherapy medicines (vincristine and temozolomide) for children and young adults with certain solid tumors that have come back or not responded to treatment. It aims to see if this combination is safe and works against the cancer.
Philadelphia, PennsylvaniaAges 1–30 - NCT06441331RecruitingPhase 1
Lu-177 edotreotide for children with SSTR-positive tumors
This trial tests a radioactive drug called Lu-177 edotreotide for children with a certain type of tumor (SSTR-positive) that hasn't responded to other treatments. The goal is to find the right dose and see how safe it is.
Philadelphia, PennsylvaniaAges 2–18 - NCT04796012RecruitingPhase 1/Phase 2
Atezolizumab plus chemo for children with recurrent solid tumors
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
Philadelphia, PennsylvaniaAges 6 months–30 years - NCT05108298Recruiting
Study to improve cancer survey reporting for young adults
This study focuses on collecting better self-reported information (from questionnaires) from young adults with cancer. It may help improve how future cancer trials understand symptoms and quality-of-life needs.
Chadds Ford, PennsylvaniaAges 18–39 - NCT06541262RecruitingPhase 1/Phase 2
Silmitasertib plus chemo for relapsed solid tumors
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Hershey, PennsylvaniaAges Up to 30 years
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting rhabdomyosarcoma studies listed above.
- Children's Hospital of Philadelphia · 5 studies
- Geisinger Medical Center · 2 studies
- Lehigh Valley Hospital-Cedar Crest · 2 studies
- Penn State Health Children's Hospital · 2 studies
- Saint Christopher's Hospital for Children · 2 studies
- UPMC Children's Hospital of Pittsburgh · 2 studies
- Christiana Care Health System-Concord Health Center
- Community Medical Center
What taking part in a rhabdomyosarcoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Rhabdomyosarcoma trials in other states
Common questions
- Are there rhabdomyosarcoma clinical trials in Pennsylvania?
- Yes. We're currently tracking 7 recruiting rhabdomyosarcoma studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a rhabdomyosarcoma study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a rhabdomyosarcoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New rhabdomyosarcoma studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.